Shandong Bio-Focus Gene Science & Technology

Shandong Bio-Focus Gene Science & Technology is a Chinese biotechnology company specializing in gene editing and cell therapy. Founded in 2009 and based in Zibo, Shandong, the company focuses on developing next-generation immunotherapies, particularly gene-edited T-cell therapies for cancer treatment. Its lead program involves PD-1 gene-deficient T lymphocytes, which entered Phase 1 clinical trials for non-small cell lung cancer (NSCLC), representing a pioneering effort in CRISPR/Cas9 and base-editing applications in oncology. Shandong Bio-Focus also collaborates with academic institutions to advance its pipeline of gene-edited cell therapies targeting solid tumors.